HIMS Stock Forecast & Price Target

Hims & Hers Health is poised for substantial revenue growth, with projections indicating an increase from approximately $50 million in fiscal year 2025 to nearly $1 billion in fiscal year 2030, primarily driven by international expansion and the enhancement of treatment offerings. The core U.S. revenue is expected to grow at around 21% annually, with a significant portion attributed to an increase in subscribers and higher revenue per subscriber, supported by effective personalization strategies that enhance customer retention. This optimistic outlook is further bolstered by favorable trends in the adoption of private healthcare, particularly in the UK, indicating a growing market for the company's services.

Hims & Hers Health has experienced a significant decline of over 20% in its stock since late July, despite more than doubling year-to-date, indicating escalating concerns regarding slowing core growth. Fundamental issues include the potential for slower adoption of personalized treatments, challenges in sustaining revenue growth while managing operating leverage, and increasing competition within the digital health sector. Additionally, the highly regulated nature of the healthcare industry poses risks that could negatively impact the company's business model, further contributing to the negative outlook on its stock.